Is iRhythm Technologies profitable in 2026?

iRhythm posted its first-ever quarterly GAAP net income and first year of positive free cash flow in FY2025. Q1 2026 revenue hit $199.4M, up 25.7% YoY, and FY2026 guidance was raised to $875M-$885M revenue with 12-13% adjusted EBITDA margin, per its April 30, 2026 earnings release.

What is iRhythm's biggest competitor?

Philips (via its 2021 BioTelemetry acquisition, new telemetry platform launched September 2025) and Boston Scientific (via its $1.22B Preventice Solutions acquisition, closed January 2021) are the closest rivals, though iRhythm still holds roughly 72% U.S. long-term continuous ECG monitoring market share as of June 2026.

Could AI replace iRhythm Technologies?

Unlikely soon. iRhythm already embeds AI (its ZEUS algorithm) in its own workflow, cutting technician review time about 50% and adding over $100M cumulative value over five years. Its moat is FDA clearance, proprietary ECG data, and Medicare reimbursement lock-in, not just software, per its April 30, 2026 earnings call.

Who owns iRhythm Technologies?

iRhythm is publicly traded on NASDAQ under ticker IRTC with no parent company. On January 12, 2026 it completed a holding-company reorganization, making iRhythm Holdings, Inc. the SEC registrant; market cap was about $3.58-3.9 billion as of July 22, 2026.

Does iRhythm Technologies face legal or regulatory trouble in 2026?

Yes. iRhythm has a $45 million securities class-action settlement (N.D. Cal., case 3:24-cv-00706) reached around June 2-3, 2026 pending court approval, an unresolved 2023 FDA warning letter on Zio AT, an unresolved 2023 DOJ subpoena, two active patent suits, and a data breach disclosed to the SEC in July 2026.

How dominant is iRhythm in cardiac monitoring?

iRhythm reports roughly 72% share of the U.S. long-term continuous ambulatory ECG monitoring market and about 15% of the mobile cardiac telemetry segment, per company disclosures cited June 5, 2026, making it the clear category leader despite competition from Philips and Boston Scientific.

Medical technology and health companies · United States

iRhythm Technologies

irhythmtech.com ↗

Maker of the Zio patch, the most-used long-term wearable heart monitor in the US.

Defensible for now

Assessed 22 July 2026 · Evidence as of 22 July 2026

Real protection, with named pressure against it.

On the recordSince 22 July 2026 · Checkable from June 2026 · Every call on the record Checkpoint: Court hearing on $45M securities settlement approval

The call

iRhythm dominates its market and just turned its first profit, but an unresolved FDA warning letter, a DOJ subpoena, patent suits, and a fresh data breach are piling up at once.

iRhythm makes wearable heart monitors that record heartbeats for days at a time, helping doctors catch irregular rhythms. The company has built a strong position through its device design, a huge library of real heart data that trains its software, and long-term contracts with insurance companies and hospitals. But the company is dealing with an unresolved FDA warning from 2023, a Justice Department investigation, a securities lawsuit heading to court in 2026, patent fights with smaller competitors, and a data breach in July 2026 that could shake doctor and payer trust. Philips bought a competitor called BioTelemetry in 2025 and is pushing its own telemetry platform, and Boston Scientific owns Preventice, so iRhythm's market share lead is not guaranteed to hold if these rivals gain traction or if legal troubles drain management focus.

Why

AI pressure: None apparent. AI reads ECGs inside iRhythm's own pipeline, cutting technician review time in half instead of replacing the company. Could AI do the core job? Unlikely.

Bigger players: Philips (BioTelemetry) and Boston Scientific (Preventice). Both bought their way into cardiac monitoring and are pushing new telemetry platforms, but neither has dented iRhythm's 72% long-term monitor share yet. Could a giant copy it? Probably.

What protects it. FDA clearances, Medicare billing codes, and a multi-billion-hour ECG dataset that took over a decade to build make copying Zio hard fast.

What would change this call

Resolution or escalation of the 2023 FDA warning letter on Zio AT into a consent decree. Would show regulatory risk materializing into operational restriction, not just legal overhang.
Outcome of Bardy Diagnostics and Welch Allyn patent suits, especially any injunction on Zio hardware. Would show whether IP risk can actually block iRhythm's core product sales.
Quarterly LTCM/MCT market share reports showing gains by Philips/BioTelemetry or Boston Scientific/Preventice. Would show whether well-funded incumbents are converting new platforms into real share erosion.

Key numbers

72% US long-term ECG monitor market share (2026-06-05)
$747.1M FY2025 revenue, up 26.2% (2025-12-31)
$549.6M cash on hand (2026-03-31)

Named risks

Unresolved 2023 FDA warning letter on Zio AT could escalate to consent decree. Severity: high
Unresolved 2023 DOJ subpoena with unknown scope or timeline. Severity: high
July 2026 data breach with claimed patient data exfiltration threatens payer trust. Severity: high
Two active patent suits (Bardy, Welch Allyn) could result in injunction on Zio hardware. Severity: medium
$45M securities settlement pending court approval, plus new shareholder investigations opened Jul 2026. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Philips (BioTelemetry)	contesting	Launched new telemetry platform Sept 2025 but iRhythm held ~72% LTCM share as of Jun 2026
Boston Scientific (Preventice)	contesting	$1.22B Preventice acquisition closed Jan 2021, competes on bundled hospital sales
Medtronic	contesting	Adjacent insertable cardiac monitors (Reveal LINQ), no direct LTCM share loss reported
Bardy Diagnostics (Baxter/Hillrom)	contesting	Active patent litigation over CAM patch technology as of 2026
AliveCor	contesting	Competes with consumer-grade AI-enabled ECG hardware, no share figures disclosed

Questions people ask

Is iRhythm Technologies profitable in 2026?: iRhythm posted its first-ever quarterly GAAP net income and first year of positive free cash flow in FY2025. Q1 2026 revenue hit $199.4M, up 25.7% YoY, and FY2026 guidance was raised to $875M-$885M revenue with 12-13% adjusted EBITDA margin, per its April 30, 2026 earnings release.
What is iRhythm's biggest competitor?: Philips (via its 2021 BioTelemetry acquisition, new telemetry platform launched September 2025) and Boston Scientific (via its $1.22B Preventice Solutions acquisition, closed January 2021) are the closest rivals, though iRhythm still holds roughly 72% U.S. long-term continuous ECG monitoring market share as of June 2026.
Could AI replace iRhythm Technologies?: Unlikely soon. iRhythm already embeds AI (its ZEUS algorithm) in its own workflow, cutting technician review time about 50% and adding over $100M cumulative value over five years. Its moat is FDA clearance, proprietary ECG data, and Medicare reimbursement lock-in, not just software, per its April 30, 2026 earnings call.
Who owns iRhythm Technologies?: iRhythm is publicly traded on NASDAQ under ticker IRTC with no parent company. On January 12, 2026 it completed a holding-company reorganization, making iRhythm Holdings, Inc. the SEC registrant; market cap was about $3.58-3.9 billion as of July 22, 2026.
Does iRhythm Technologies face legal or regulatory trouble in 2026?: Yes. iRhythm has a $45 million securities class-action settlement (N.D. Cal., case 3:24-cv-00706) reached around June 2-3, 2026 pending court approval, an unresolved 2023 FDA warning letter on Zio AT, an unresolved 2023 DOJ subpoena, two active patent suits, and a data breach disclosed to the SEC in July 2026.
How dominant is iRhythm in cardiac monitoring?: iRhythm reports roughly 72% share of the U.S. long-term continuous ambulatory ECG monitoring market and about 15% of the mobile cardiac telemetry segment, per company disclosures cited June 5, 2026, making it the clear category leader despite competition from Philips and Boston Scientific.

Timeline

2026-07-15iRhythm discloses data breach and extortion attempt to SEC after June 8 unauthorized access
2026-06-21Final Medicare LCD L40255 on temporary nontherapeutic ambulatory cardiac monitoring takes effect
2026-06-02$45M securities class-action settlement reached, pending court approval
2026-04-30Q1 2026 revenue $199.4M (+25.7% YoY); FY2026 guidance raised to $875M-$885M
2026-02-18FY2025 results announced: first-ever GAAP profitable year, revenue $747.1M
2026-01-12Holding-company reorganization completed; iRhythm Holdings, Inc. becomes SEC registrant
2025-09-01Philips launches new telemetry platform via BioTelemetry
2025-05-01Zio LTCM commercial launch in Japan via Senko Medical Instrument
2023-06-06FDA issues warning letter over Zio AT medical device reporting failures
2021-01-15Boston Scientific closes $1.22B acquisition of Preventice Solutions

Revision history

22 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Abridge Seegene Olympus Corporation

More in Medical technology and health companies →

Sources